BRCA1 carriers more frequently develop triple-negative breast cancers, while BRCA2 mutation carriers exhibit a broader tumor spectrum, including increased risks of prostate, male breast, and pancreatic cancer [14,16]. Here, BRCA1 is linked to neoplasm.